Le Lézard
Classified in: Health, Business
Subjects: LIC, MAT

Encore Life, LLC and WholeScripts, LLC Announce Partnership Agreement


TULSA, Okla., June 1, 2020 /PRNewswire/ -- Encore Life, the only practitioner-exclusive professional grade Hemp supplement manufacturer, and WholeScripts, powered by XYMOGEN, the fastest growing supplier of nutritional supplements, have signed a partnership agreement naming Encore Life as the premier Hemp Extract product line offered via WholeScripts' sales channels. This partnership grants the companies' valued practitioner partners easier access to quality Hemp products through one single online platform, streamlining the order process and meeting increasing patient demand. The initial product release will include Encore Life's Broad-Spectrum PRO series oils, available in 750 mg, 1500 mg, and 3000 mg concentrations.

"We're thrilled to have WholeScripts offer our professional grade Hemp products as our trusted partner.  WholeScripts powered by XYMOGEN, is known for their top-quality nutritional supplements, and this partnership grants the practitioner and their patients complete confidence in the quality of their Hemp product purchase," said Sean DeWitt, CEO of Encore Life. "Encore Life is committed to only offering its innovative products through practitioners, exclusively, and given WholeScripts' shared vision it was an easy decision for our company."

"Encore Life, a premier brand of Hemp supplements, was heavily requested by our physicians and representatives," said Mike Mahoney, Senior Vice President of WholeScripts. "Our team is extremely excited to be offering Encore Hemp supplements as one of our first brand partners at WholeScripts. Encore's support of the practitioner market, quality and purity makes them a great fit to continue our mission for a unique and secure practitioner relationship."

About Encore Life

Established in 2016, Encore Life focuses on innovative, professional grade Hemp Extract products and delivery modalities to ensure a unique and consistent patient experience. Encore uses USA grown, non-GMO, CO2 extracted Hemp oil in the manufacturing process to provide the purest products possible, available exclusively via healthcare practitioners. For more information about Encore Life, please visit www.myencore.life.

About WholeScripts

WholeScripts, a one-stop site for professional-grade nutritional and herbal supplements, is the fulfillment arm of XYMOGEN and the ONLY site where authentic XYMOGEN formulas can be ordered. Backed by exceptional customer service, WholeScripts offers unique user experiences tailored to both patients and practitioners.

SOURCE Encore Life


These press releases may also interest you

at 10:02
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

at 10:00
Minister Responsible for Relations with the First Nations and the Inuit Ian Lafrenière today submitted in the National Assembly the third annual report on the administration of the Act to authorize the communication of personal information to the...

at 10:00
Cobb Outpatient Detox has opened a new facility in Marietta, GA, providing outpatient drug and alcohol detox services. The center aims to assist individuals in overcoming addiction while balancing their work and family commitments. Located near major...

at 10:00
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and...

at 10:00
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...



News published on and distributed by: